How much is ANI Pharmaceuticals stock worth?
One share of ANIP stock can currently be purchased for approximately $39.32. How much money does ANI Pharmaceuticals make? ANI Pharmaceuticals has a market capitalization of $559.96 million and generates $208.48 million in revenue each year.
Is Antani Pharmaceuticals a good stock to buy?
ANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
What did Ani sell for $210 million?
The companies, which announced their $210 million deal in March, agreed to sell ANI's development rights to generic sulfamethoxazole-trimethoprim oral suspension, a combination of antibiotics, and assets related to generic dexamethasone, used to treat inflammation and arthritis.
Is ANI Pharmaceuticals's P/E ratio good or bad?
The P/E ratio of ANI Pharmaceuticals is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of ANI Pharmaceuticals is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What does ANI Pharmaceuticals make?
ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products.
Where is Ani Pharmaceuticals located?
Baudette, MinnesotaOur two pharmaceutical manufacturing facilities located in Baudette, Minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment.
What is the official website of ANI Pharmaceuticals?
How much does Ani Pharmaceuticals make?
The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.
Is ANI Pharmaceuticals a buy?
How much money does ANI Pharmaceuticals make? ANI Pharmaceuticals has a market capitalization of $409.24 million and generates $208.48 million in revenue each year. The specialty pharmaceutical company earns $-22,550,000.00 in net income (profit) each year or $2.87 on an earnings per share basis.
Who is the CEO of ANI Pharmaceuticals?
ANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Does ANI pay dividends?
1 employees have rated ANI Pharmaceuticals CEO Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among ANI Pharmaceuticals' employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What is ANI Pharmaceuticals?
ANI Pharmaceuticals does not currently pay a dividend.
When is the ANI annual meeting 2021?
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, ... [Read more...]
